Simplified quantification of FDG metabolism in tumors using the autoradiographic method is less dependent on the acquisition time than SUV

Nuclear Medicine and Biology

Volumn 38, Issue 6, 2011, Pages 835-841

  Burger, Irene A ^a   Burger, Cyrill ^a   Berthold, Thomas ^a   Buck, Alfred ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Automatic injector; Autoradiographic method; Population based input curve; Quantification of FDG uptake; Uptake time

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; CORRELATIONAL STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TUMOR LEVEL; DRUG UPTAKE; ESOPHAGUS CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INFUSION SYSTEM; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG SMALL CELL CANCER; MALE; MATHEMATICAL MODEL; METASTASIS; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE STUDY; SARCOMA; SIMULATION; THORAX TUMOR; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; THORACIC NEOPLASMS; TIME FACTORS;

EID: 80051682753     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.02.003     Document Type: Article

References (25)

1. 18F-FDG PET in oncology. J Nucl Med 2008, 49:480-508.
2. 18-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003, 44:224-239.
3. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007, 48:771-775.
4. Ryu J.S., Choi N.C., Fischman A.J., Lynch T.J., Mathisen D.J. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002, 35:179-187.
5. Wahl R.L., Quint L.E., Greenough R.L., Meyer C.R., White R.I., Orringer M.B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994, 191:371-377.
6. Hany T.F., Steinert H.C., Goerres G.W., Buck A., von Schulthess G.K. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002, 225:575-581.
7. Lowe V.J., DeLong D.M., Hoffman J.M., Coleman R.E. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995, 36:883-887.
8. Sadato N., Tsuchida T., Nakaumra S., Waki A., Uematsu H., Takahashi N., et al. Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours. Eur J Nucl Med 1998, 25:559-564.
9. Houseni M., Chamroonrat W., Zhuang J., Gopal R., Alavi A., Zhuang H. Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med 2010, 51:535-542.
10. Weber W.A., Ziegler S.I., Thodtmann R., Hanauske A.R., Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999, 40:1771-1777.
11. 18F-FDG PET in malignant tumors. J Nucl Med 2008, 49:1804-1808.
12. Graham M.M., Peterson L.M., Hayward R.M. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000, 27:647-655.
13. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999, 26:22-30.
14. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
15. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983, 3:1-7.
16. Hunter G.J., Hamberg L.M., Alpert N.M., Choi N.C., Fischman A.J. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996, 37:950-955.
17. 18F-FDG PET studies. J Nucl Med 2006, 47:945-949.
18. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977, 28:897-916.
19. Huang S.C., Phelps M.E., Hoffman E.J., Sideris K., Selin C.J., Kuhl D.E. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980, 238:E69-E82.
20. Vriens D., de Geus-Oei L.F., Oyen W.J., Visser E.P. A curve-fitting approach to estimate the arterial plasma input function for the assessment of glucose metabolic rate and response to treatment. J Nucl Med 2009, 50:1933-1939.
21. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122S-1250S.
22. Beaulieu S., Kinahan P., Tseng J., Dunnwald L.K., Schubert E.K., Pham P., et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 2003, 44:1044-1050.
23. Thie J.A., Hubner K.F., Smith G.T. Optimizing imaging time for improved performance in oncology PET studies. Mol Imaging Biol 2002, 4:238-244.
24. Spence A.M., Muzi M., Graham M.M., O'Sullivan F., Krohn K.A., Link J.M., et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med 1998, 39:440-448.
25. Takagi S., Takahashi W., Shinohara Y., Yasuda S., Ide M., Shohtsu A., et al. Quantitative PET cerebral glucose metabolism estimates using a single non-arterialized venous-blood sample. Ann Nucl Med 2004, 18:297-302.